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Abstract 
A systematic literature review was conducted to evaluate the clinical effectiveness and safety of 
treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for 
intensive treatment.  Criteria for inclusion of trials were established prior to the literature review. 
A search of Medline, Embase and the Cochrane library d tabases was conducted to identify 
phase II or III randomised controlled trials (RCTs), published from January 1st 994 to 29th May 
2016. Relevant conference abstracts, citation lists from included articles, published guidelines 
and on-going clinical trial databases were also search d. Articles were included if they evaluated 
any single agent or combination of treatments in adult patients with relapsed/refractory MCL 
who had received at least one prior line of therapy. Seven RCTs were identified. Only one 
treatment appeared in more than one trial, and therefore results from each trial could not be 
quantitatively pooled by meta-analysis. Lack of common comparators, differences in baseline 
characteristics and inclusion and exclusion criteria and variance in the response criteria used to 
measure outcomes, made comparison of results difficult. Although the direction of effect for PFS 
and OS was in favour of the experimental drug in all tri ls, PFS was statistically significant in 
five and OS in two. None showed statistical significance for both. There are a noticeable lack of 
RCTs evaluating treatments for patients with relapsed/refractory MCL making meaningful 
comparisons of effectiveness across trials rather difficult. This trend continues as all bar one of 
the 85 on-going trials in this area are single arm studies. RCTs are required to enable better 
evaluation of the optimal treatment regimen for this group of patients.  
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Introduction  
Mantle cell lymphoma (MCL) is a rare B-cell malignancy belonging to the non-Hodgkin 
lymphoma (NHL) group of diseases1 and represents 3-10% of all newly diagnosed NHL cases2,3 
(figure 1), with an incidence of approximately 1 per 100,000 population in Europe4 and the 
USA.5 MCL more commonly affects men with a median age at presentation of 65 years2 and is 
typically at an advanced stage at diagnosis, Ann Arbor stage III and IV.6  
The hallmark of MCL is the chromosomal translocation t(11;14)(q13;q32), resulting in 
overexpression of the cell cycle protein cyclin D1 and cell cycle dysregulation.7 There are two 
main variants; classical MCL is the more common form f the disease2 and has an overall 
survival (OS) of approximately 4.5 years. Blastoid variant is rarer but is associated with a more 
aggressive clinical course and poorer prognosis, with an OS of approximately 15 months.8 
MCL frequently has an aggressive clinical course and lthough initial therapy can achieve high 
overall response rates of between 60% and 97%,11 these tend to be short lived and the majority of 
patients will eventually relapse and die from their disease. Some patients, however, have a more 
indolent form of the disease. Although it is difficult to identify this group, there are some 
markers eg SOX11 negativity, that may help to distingu sh it from a more aggressive phenotype. 
Ongoing research in the UK12 aims to characterise the differences in a prospective trial. Some 
clinicians now adopt a “watch and wait” management approach with these patients if they are 
asymptomatic.4  
First line treatment options will depend on the agend fitness of the patient. Intensive frontline 
cytarabine-based treatments are reserved for the younger, fitter patient due to their associated 
toxicity, and are commonly consolidated with an autologous transplant.2,4,7  However, the 
majority of patients are older or more frail at presentation and this approach is not feasible. There 
are a number of immuno-chemotherapy options available for this group of patients4 including 
bendamustine and rituximab (B-R), rituximab, cycloph sphamide, doxorubicin, vincristine, 
prednisolone (R-CHOP) or bortezomib, rituximab, cyclophosphamide, doxorubicin and 
prednisone (VR-CAP) regimens with response rates ranging from 60% to 95% and median 
progression free survival (median PFS) of up to 5 years. Rituximab maintenance plays a role in 
sustaining response following an R-CHOP induction. For the more frail patients who are 
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unsuitable for immuno-chemotherapy, less intensive therapies are recommended including 
chlorambucil, bendamustine or cladribine, usually given in combination with rituximab,2,7,14 and 
the combination of rituximab, vincristine, cyclophosphamide and prednisolone2 (R-CVP). 
There is no consensus as to what the standard of care or relapsed/refractory disease should be. 
Experts recommend an alternative immuno-chemotherapy to that which was used initially6 and 
selection of treatment will depend on a number of factors, including the presence of co-
morbidities, patient fitness and patient wishes. As many patients are not suitable for an intensive 
treatment approach, there are several options recommended in guidelines in the 
relapsed/refractory setting2,4,15 for the older patient. This systematic review therefo e evaluated 
the available evidence for therapeutic options for patients with relapsed/refractory mantle cell 
lymphoma who were unsuitable for an intensive treatm nt approach.   
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Methods 
The review methodology was pre-defined in a protocol available in the supplementary 
information and registered on Prospero. Randomised controlled trials were included if they met 
the following criteria: population – adult patients with relapsed/refractory MCL who had 
received at least 1 prior line of therapy who were not eligible for intensive treatment or 
transplant; intervention – any single agent or combination of agents including chemotherapy, 
immunotherapy, immuno-chemotherapy, targeted agents, xcluding intensive treatment and 
transplant; comparator – any single agent or agents as above; outcomes – overall survival (OS), 
progression free survival (PFS), overall response rat  (ORR) and safety. Electronic searches 
were undertaken in Medline, Embase and the Cochrane Library from January 1994 (as MCL was 
accepted as a separate entity in 1994) to 29th May 2016. In addition conference proceedings from 
the annual congresses of the American Society of Haematology (ASH), the European 
Haematology Association (EHA), the American Society of Clinical Oncology (ASCO), the 
European Society of Medical Oncology (ESMO), were searched for the preceding 5 years to find 
unpublished trials. Citation lists from included studies, review articles and published guidelines 
from the National Comprehensive Cancer Network (NCC), ESMO, ASH, the British Society of 
Haematology (BSH) and the European Mantle Cell Lymphoma Network were also searched. 
Ongoing trials were identified from two research datab ses (www.clinicaltrials.gov and 
www.clinicaltrialregister.eu) up to the 24th December 2016.  
Search terms for the population included ‘Lymphoma, M ntle-cell Lymphoma, Non-Hodgkin 
Lymphoma, B-Cell Lymphoma’, for the intervention and control search terms included ‘Drug 
therapy [MeSH]  OR immunotherapy (MeSH) OR molecular targeted  therapy (MeSH) OR 
biological therapy [MeSH] OR combined modality therapy [MeSH] OR antineoplastic agents 
(MeSH) OR lenalidomide OR ibrutinib OR thalidomide OR bortezomib OR temsirolimus OR 
everolimus OR BTK inhibitor OR proteasome inhibitor’. Full details of the search strategies used 
are shown in appendices 1 and 2. There were no restrictions on language. 
Two reviewers (MP and MK) independently screened th search results for potential 
inclusion/exclusion using the title and abstract, wi h full paper copies obtained to confirm 
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inclusion into the review. The final decision for inclusion of articles was based on agreement 
between the reviewers.  
Results 
A total of 1746 articles were identified from the search as outlined in the PRISMA diagram 
(figure 1). After 430 duplicates were removed, 1316 articles were initially screened for inclusion 
from the title and abstract, with 27 published articles retrieved for full text screening. Seven 
randomised controlled trials met the inclusion criteria and are included in the 
review.17,18,19,20,21,22,23. There was full agreement between the reviewers with regard to included 
articles. The concordance between reviewers is a reult of both the clearly defined criteria and 
the paucity of trials in this setting. 
Table 1 provides a summary of the trial design for the included trials together with the treatment 
regimens for each trial. Follow up amongst the trials varied with the shortest median follow up of 
15.9 months in the trial conducted by Trneny et al23 nd the longest median follow up of 96 
months reported by Rummel and colleagues.22 All three trials that included a variety of non-
Hodgkin lymphoma sub-types in the trial18,19,22 reported separate outcomes for the MCL sub-
population and were included in this review. Only one treatment, temsirolimus, appeared in more 
than one trial. 
Data was extracted from the articles by one reviewer (MP) which was checked by a second 
reviewer (MK). Study and patient characteristics were xtracted as well as details of the 
intervention and control. Outcomes data collected wre overall survival, progression free 
survival, tumour responses and data on safety restricted to grade 3 and 4 haematological 
toxicities.  
Only a descriptive analysis of included trials was feasible due to heterogeneity of study 
populations and interventions. 
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Figure 1 - PRISMA Diagram 
 
           Potentially relevant records identified: 
• Medline (n=703) 
• Embase (n=632 
• Cochrane (n=58) 
• PubMed (n=353)            Total n=1746 
 
Unique records after duplicates removed:  
n = 1316 
Records excluded: n= 1289 
• Biomarker/prognosis (n=31) 
• Reviews/Commentary/Letters (n=156) 
• Study Design (n=147) 
• Population (n=603) 
• Intervention (n=296) 
• Preclinical (n=25) 
• Outcomes/Analysis (n=31) 
 
Records retrieved for full text screening: 
n =27 
Records excluded from full text screening: 
n=16 
• Population (n=7) 
• Study Design (n=6) 
• Intervention (n=3) 
Records for review:  
n = 11   
Records excluded: n=4 
• Dose scheduling studies (n=4) 
Total trials for final review:  
n = 7   
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Reference Design Treatment 
Invest            Control                                                                        
Number of MCL 
Patients
Invest            Control 
Inclusion Criteria 
 
Dreyling M., 201617 
 
 
Phase III, multicentre, open label, 
randomised 1:1, ITT, IWG 2007  
 
 
Ibrutinib 
 
Tems 
 
139 
 
141 
 
R/R MCL, at least 1 prior rituximab-containing therapy,  
ECOG PS 0-1 
 
Forstpointner R., 200418 
 
 
Phase III, multicentre, open label, 
randomised 1:1, ITT, IWG 1999 
 
 
R-FCM 
 
FCM 
 
24 
 
26 
 
R/R MCL (35%), FL (49%) and Lymphoplasmocytic 
(11%), Other (5%), at least 1 prior chemo inc. HSCT, PS 
not stated 
 
Forstpointner R., 200619 
 
 
Phase III, multicentre, open label, 
randomised 1:1, ITT, IWG 1999  
 
 
Ritux 
maint 
 
No 
treatment 
 
24 
 
26 
 
R/R MCL, FL (as above) patients achieving CR or PR on 
induction R-FCM, PS not stated 
 
Furtado M., 201420 
 
 
Phase II,  multicentre, open label, 
randomised 1:1, ITT, IWG 2007  
 
 
V-CHOP 
 
CHOP 
 
23 
 
23 
 
R/R MCL, at least 1 prior therapy, ECOG PS <2 
 
Hess G., 200921 
 
 
Phase III, multicentre, open label,  
randomised 1:1:1, ITT, IWG 2007 
 
 
Tems 
HD vs 
LD 
 
IC* 
 
HD 54 
LD 54 
 
53 
 
R/R MCL, 2-7 prior therapies, must have included an 
alkylating agent, an anthracycline and rituximab, ECOG 
PS <2 
 
Rummel M., 201622 
 
 
Phase III, multicentre, open label, 
randomised 1:1, per proto, response 
criteria not stated 
 
 
B-R 
 
F-R 
 
24 
 
23 
 
R/R MCL (21%), FL (51%), MZL (8%), WM (11%) 
Unclassified (9%), at least 1 prior therapy, WHO PS 0-2, 
 
Trneny M., 201623 
 
Phase II,  multicentre, open label, 
randomised 2:1, ITT, IWG 2007 
 
Lenalid 
 
IC** 
 
170 
 
84 
R/R MCL, at least 1 prior comb chemo with an alkylating 
agent + one or more of: anthracycline, cytarabine, or 
fludarabine +/- ritux, ECOG PS 0-2 
     Invest=investigational drug; R/R=relapsed or refractory disease; MCL=mantle cell lymphoma; FL=follicular lymphoma; MZL=marginal zone lymphoma; 
WM=Waldenstrom’s macroglobulinaemia; HSCT=haematopoitic stem cell transplant; CR=complete response; PR=partial response; PS=performance status; 
tems=temsirolimus; FCM=fludarabine + cyclophosphamide + mitoxantrone; R-FCM= rituximab + FCM as before; CHOP =cyclophosphamide + doxorubicin + 
vincristine + prednisolone; V-CHOP=bortezomib +CHOP as before; IC=investigators choice chemotherapy; B-R=bendamustine + rituximab; F-R=fludarabine + 
rituximab; lenalid=lenalidomide; ITT=intention-to-treat analyses; per proto=per protocol analyses; IWG 1999=international working group response criteria 
1999; IWG 2007=international working group revised r sponse criteria 2007 
 
Table 1 – Trial Design of Included Studies                   
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Regimens in Table 1 
 
Ibrutinib  Oral 560mg daily until progression 
 
Tems IV temsirolimus 175mg on days 1,8,15 of cycle 1 followed by 75mg on days 1,8,15 subsequent 21 day cycles until progression or 
unacceptable toxicity 
 
FCM  IV fludarabine 25mg/m2 on days 1-3 + IV cyclophosphamide 200mg/m2 on days 1-3 + IV mitoxantrone 8mg/m2 on day 1 for 4 cycles 
 
R-FCM  IV rituximab 375mg/m2 day 0 + FCM as before for 4 cycles 
 
Rituximab 
maintenance 
2 courses of IV rituximab at 3 and 9 months after completion of induction, each course = 4 doses of IV ritux 375mg/m2 on 4 consecutive 
weeks 
CHOP IV cyclophosphamide 750mg/m2 + IV doxorubicin 50mg/2 + IV vincristine 1.4m/m2 to max of 2mg on day 1 of each cycle + oral 
prednisolone 100mg/day for max of 8 cycles 
 
V-CHOP IV bortezomib 1.6mg/m2 on days 1,8 of 21 day cycle + CHOP as before for max 8 cycles 
 
Tems HD IV temsirolimus as before until progression or unacceptable toxicity  
 
Tems LD IV temsirolimus 175mg on days 1,8,15 of cycle 1 followed by 25mg on days 1,8,15 subsequent 21 day cycles until progression or 
unacceptable toxicity   
 
B-R IV bendamustine 90mg/m2 on days 1,2 + IV rituximab 375mg/m2 on day1 every 4 weeks for max 6 cycles 
 
F-R IV fludarabine 25mg/m2 on days 1-3 + rituximab as before for max 6 cycles 
 
Lenalid Oral lenalidomide 25mg on days 1-21 of 28 day cycle until progression or unacceptable toxicity 
 
IC* IV gemcitabine 1000mg/m2 on days 1,8,15 every 28 days for max 6 cycles OR IV fludarabine 25mg/m2 or oral fludarabine 40mg/m2 on days 
1-5 every 28 days for max 6 cycles OR oral chlorambucil 0.1-0.2mg/kg daily for 3-6 weeks OR IV cladribine 5mg/m2 daily for 5 days every 
28 days OR IV etoposide 50-150mg/m2 daily for 3-5 days every 21-28 days OR oral thalidomide 200mg daily OR IV vinblastine 10mg 
weekly OR IV alemtuzumab 30mg/day 3 times/week OR oral lenalidomide 25mg daily for 28 days 
 
IC** IV rituximab 375mg/m2 on days 1,8,15,22 and then once every 56 days until progression OR IV gemcitabine as before OR either fludarabine 
as before OR IV chlorambucil 40mg/m2 per month divided over days 3-10 until progression OR IV cytarabine 1-2g/m2 on days 1,2 every 28 
days for max 6 cycles 
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Quality Assessment of Studies 
The quality of each trial was assessed using The Cochrane Collaboration’s tool for assessing risk 
of bias. Assessment of blinding of participants andpersonnel was not applicable as all trials were 
open label and have therefore been listed as unclear due to the restrictions of choice within the 
tool. A full assessment of each trial is given in appendix 3. Overall two trials17,23 were judged to 
be at low risk of bias across all domains, five trials18,19,20,21,22 provided insufficient information 
on which to judge bias in some domains, and two trials20,22 were judged to have some elements 
of high risk of bias (some trials fell into more than one category). Rummel et al22 were judged to 
have detection bias by not referencing response crit ria. Furtado et al20 were judged to have 
selection and reporting bias in their trial based on differences in baseline characteristics between 
the two groups and not reporting pre-specified outcmes. A summary of the risk of bias is shown 
in figure 2.  
 
 Baseline Characteristics 
The inclusion criteria were broadly similar between the trials with a couple of notable 
differences. Hess et al21 required patients to have had two or more prior the apies, the remaining 
trials only required one. All trials, where stated, included patients with an ECOG performance 
status (PS) of up to 2. Dreyling et al17 restricted this to PS 1. The median age of included patients 
was similar across trials, with median age between 67 years and 70 years of age in the majority 
of the trials.  
The baseline characteristics are summarised in table 2 and were generally well balanced between 
the treatment arms in the majority of the trials. Three trials20,21,23 did report an imbalance in some 
baseline characteristics. In the first the treatment groups differed with respect to blastoid variant, 
the median number of prior lines of treatment and prior bortezomib therapy,21 the second 
differed with respect to the proportion of male patients, time since diagnosis and prior 
rituximab20 and the final one differed with respect to tumour b den, bulky disease, LDH levels, 
number of prior therapies and numbers of patients with refractory disease.23 
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*Assessment of blinding of participants and personnel was not applicable as all trials were open 
label. The trials have been listed as unclear risk of bias due to the restrictions of choice within 
the bias tool  
                     Low risk of bias 
                     Unclear risk of bias 
                     High risk of bias 
 
Figure 2 - Risk of Bias Summary 
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Invest=investigational drug; sMIPI=simplified mantle cell lymphoma international prognostic index; HD=high dose; LD=low dose. *% of 1 previous and 2 
previous therapies added together for this group; **These are rates of 2-3 previous therapies vs 4-7 previous therapies; ***2% missing in both arms; ++<3 years 
v > 3 years; ibr=ibrutinib; tems=temsirolimus; R-FCM=rituximab, fludarabine, cyclophosphamide + mitoxantrone; rit main=rituximab maintenance; 
obs=observation; V-CHOP=bortezomib, cyclophosphamide, doxorubicin, vincristine + prednisolone; IC=investigator’s choice; B-R=bendamustine + rituximab; 
F-R=fludarabine + rituximab; lenal=lenalidomide 
Table 2 – Baseline Characteristics of Trial Population
Reference Median Age 
(years) 
 
 
   
Invest   
Cont         
Median Time from 
Original Diagnosis 
to Randomisation 
(months) 
     
  Invest        Control   
Type of Histology                                                             
Blastoid vs Classical 
(%) 
 
 
  Invest                Control 
sMIPI                                 
Low vs Med vs High (%) 
 
 
  
  Invest               Control 
Relapsed vs Refractory 
(%) 
 
 
 
   Invest                 Control 
Prior Line of Therapy                                                           
1-2 vs >2 (%) 
 
 
     
   Invest                  Control 
 
Dreyling M.,  
201617 
Ibr v tems 
 
67 
 
68 
 
38.9 
 
46.23 
 
12 v 88 
 
12 v 88 
 
32v47v22 
 
30v49v21 
 
74 v 26 
 
67 v 33 
 
68 v 32 
 
66 v 34 
 
Forstpointner R. 
200418 
R-FCM v FCM 
 
65 
 
63 
 
24 for total 
population 
 
Not stated 
 
Not stated 
 
Not stated 
 
83 v 17* 
 
84 v 17* 
 
Forstpointner R. 
200619 
Rit main v obs 
 
63 
 
63 
 
35 for total 
population 
 
Not stated 
 
Not stated 
 
Not stated 
 
97 v 4* 
 
100 v 0* 
 
Furtado M., 
201420 
V-CHOP v CHOP 
 
69 
 
71 
 
24.7 
 
19.7 
 
Not stated 
 
Not stated 
 
Not stated 
 
Not stated 
 
Hess G.,  
200921 
Tems v IC 
HD 
68 
 
64.5 
 
HD 49.6 
 
48.5 
HD 
0 v 85 
 
7 v 74 
 
Not stated 
 
Not stated 
HD 52 v 48**  
39 v 61** 
LD 
68.5 
 
LD 47.7 
LD 
17 v 65 
LD 59 v 41** 
 
Rummel M., 
201622  
B-R v F-R 
 
71.6 
 
69.4 
 
Not stated 
 
 
Not stated 
 
Not stated 
 
96 v 4 
 
95 v 5 
 
79.1 v 20.8 
 
87 v 13 
 
Trneny M., 
201623 
Lenal v IC 
 
68.5 
 
68.5 
 
54 v 45 
++ 
 
52 v 46 
++ 
 
Not stated 
 
 
25v39v35 
*** 
 
25v44v30 
*** 
 
59 v 41 
 
70 v 30 
 
73 v 26 
 
71 v 29 
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Effectiveness of Treatments  
Table 3 provides a summary of the progression free survival (PFS), overall survival (OS) and 
overall response rates (ORR) reported for MCL patients in the included trials. All the trials 
reported an improvement in PFS with the experimental drug which was statistically significant in 
all except two of the trials.18,20 All the trials reported an improvement in OS in favour of the 
experimental arm, although not all the trials were powered to demonstrate a statistical difference 
in OS between the two groups.  
Dreyling and colleagues17 compared the oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib 
to the intravenous mTOR pathway inhibitor, temsirolimus, in patients who had been treated with 
at least 1 prior rituximab-containing therapy. With a median follow up of 20 months, PFS was 
significantly improved with ibrutinib when compared to temsirolimus (HR 0.43 [95% CI 0.32-
0.58]; p<0.0001) with a median PFS with ibrutinib of 14.6 months vs 6.2 months with 
temsirolimus.  There was a 24% relative reduction in the risk of death in patients receiving 
ibrutinib compared to temsirolimus (HR 0.76 [95% 0.53-1.09]; p=0.1324). Median OS was not 
reached in the ibrutinib arm compared with 21.3 months in the temsirolimus arm. It was noted 
that 23% of the patients receiving temsirolimus crossed over to the ibrutinib arm. The ORR as 
assessed by independent review was significantly higher for ibrutinib than for temsirolimus (72% 
vs 40%, (p<0.0001). Additionally, complete response (CR) rates were superior (19% with 
ibrutinib vs 1% with temsirolimus, odds ratio=3.98 [2.38-6.65]). At 18 months the estimated rate 
of response was 58% (range 46-68%) for ibrutinib compared to 20% (range 9-35%) for 
temsirolimus.
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` 
 
Table 3 – Efficacy Outcomes for MCL Patients in the Included Trials      
 
 
 
 
Reference
Outcome 
Analysis
median PFS 
HR                              
(95%  CI)
p value median OS 
HR                           
(95%  CI)
p value ORR 
Odds Ratio             
(95%  CI)
p value CR
Odds Ratio             
(95%  CI)
p value PR
Odds Ratio             
(95%  CI)
Dreyling M., 2016 ITT 14.6 vs 6.2 
0.43                                 
(0.32 - 0.58)
<0.0001 NR* vs 21.3
0.76                        
(0.53 - 1.09)
0.1324 72 vs 40 NR** 0.0001 19 vs 1
3.98         
(2.38-6.65)
NR** NR** NR**
Forstpointner R., 2004 ITT 8 vs 4 NR** 0.3887
NR* vs 11 
(estimated)
NR** 0.0042 58 vs 46 NR** 0.282 29 vs 0 NR** NR** 29 vs 46 NR**
Forstpointner R., 2006
Patients 
with initial 
R-FCM 
therapy
14 vs 12# NR** 0.049 45% vs 9%† NR** NR** NR** NR** NR** NR** NR** NR** NR** NR**
Furtado M., 2014 ITT 16.5 vs 8.1
0.6                                
(0.31 - 1.15)
0.12 35.6 vs 11.8
0.37                        
(0.16 - 0.83)
0.01 82.6 vs 47.8
0.14                                
(0.03 - 0.62)
0.01 34.8 vs 21.7 
0.52                                 
(0.14 - 1.93)
0.33 47.8 vs 26.1 
0.39                         
(0.11 - 1.33)
Hess G., 2009© ITT 4.8 vs 1.9
0.44                           
(0.25 - 0.78)
0.0009 12.8 vs 9.7
0.80                     
(0.50 - 1.28)
0.3519 22 vs 2 NR** 0.0019 2 vs 2 NR** NR** 20  vs 0 NR**
Rummel M., 2016
Per 
protocol
17.6 vs 4.7
0.45                          
(0.22 - 0.76)
0.01 35.3 vs 20.9 NR** NR** 70.8 vs 26.1 NR** NR** 37.5 vs 13 NR** NR** 33.3 vs 13 NR**
Trneny M., 2016 ITT 8.7 vs 5.2
0.61                        
(0.44 - 0.84)
0.004 27.9 vs 21.2
0.89                            
(0.62 - 1.28)
0.45 40 vs 11 NR** 0.001 5 vs 0 NR** NR** 35 vs 11 NR**
 NR* = not reached; NR** = not reported; # = median response duration; † = ongoing remissions beyond 2 years; © = results for higher dose; ITT = intent to treat; median PFS = median progression free survival; median OS = 
median overall survival; ORR = overall response rat;                                           CR = complete response; PR = partial response; 
Partial Response (% )Complete Response (% )Overall Response Rate (% ) Overall Survival (months)Progression Free Survival (months)
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Hess et al21 compared two IV temsirolimus regimens (175mg weekly for 3 weeks followed by 
either 75mg weekly or 25mg weekly) to investigator’s choice (IC) chemotherapy in patients who 
had received between 2 and 7 prior therapies, which must have included an alkylating agent, an 
anthracycline and rituximab. PFS was statistically significantly improved with the higher dose 
temsirolimus when compared to the IC cohort (HR 0.44 [97.5% CI 0.25-0.78] p=0.0009). A non-
significant improvement in PFS was noted with the lower dose (HR 0.65 [97.5% CI 0.39-1.10] 
p=0.062). A longer median PFS was observed in the high dose cohort compared to IC (4.8 
months vs 1.9 months) and the low dose cohort (3.4 months vs 1.9 months with IC). Higher dose 
temsirolimus resulted in a 20% relative reduction in the risk of death when compared to IC 
chemotherapy (HR 0.80 [95% CI 0.50-1.28] p=0.35) but did not reach statistical significance. 
The lower dose achieved a 4% relative reduction in the risk of death compared to IC (HR 0.96 
[95% CI 0.60-1.54] p=0.87).  The final median OS analysis demonstrated an improvement in 
favour of the higher dose of temsirolimus, compared with IC (12.8 months vs 9.7 months, 
p=0.35). The median OS observed with the lower dose c hort was 10 months (p=0.87). High 
dose temsirolimus resulted in a superior ORR when compared to IC chemotherapy (22% vs 2%, 
p=0.0019). The ORR with low dose temsirolimus was 6% (p=0.61). The complete response rate 
with high dose temsirolimus was comparable to IC (2% vs 2%) whilst the partial response rate 
was improved (20% vs 0%). 
The addition of rituximab (an anti-CD20 monoclonal antibody) to a combination of fludarabine, 
cyclophosphamide and mitoxantrone chemotherapy (R-FCM) was compared to FCM alone by 
Forstpointner and colleagues18 in a mixed population of lymphoma sub-types (49% had follicular 
lymphoma, 35% had MCL and 11% had lymphoplasmocytic/cytoid lymphoma) who had 
received at least 1 prior line of treatment. The trial was stopped early with 128 patients recruited 
due to a significant advantage observed in favour of R-FCM. PFS was significantly improved 
with R-FCM compared to FCM alone in the overall population (median PFS 16 months vs 10 
months; p=0.038) after a median follow up of 18 months. In an exploratory analysis for 
histological sub-groups, a shorter median PFS was observed for the MCL population compared 
with the total population (R-FCM 8 months vs 4 months FCM; p=0.389). This trial had a second 
randomisation19 to maintenance rituximab or no maintenance for patients who had achieved a 
CR or PR. Despite the median duration of response (DoR) for MCL patients being similar in 
both arms (14 months maintenance vs 12 months no mainten nce, p=0.049), a higher proportion 
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of MCL patients receiving maintenance rituximab exprienced ongoing remissions beyond 2 
years (45% vs 9%). A statistically significant benefit in median OS was observed in the cohort of 
MCL patients receiving R-FCM compared to FCM (not reached vs 11 months [estimated]; 
p=0.0042). These patients represented 35% of the toal p pulation. In addition, at 2 years 65% of 
MCL patients receiving R-FCM were still alive compared to 35% of patients treated with FCM. 
R-FCM resulted in a ORR when compared to FCM alone (58% vs 46%, p=0.282). More MCL 
patients experienced a complete response with R-FCM than with FCM (29% vs 0%), although 
more patients in the FCM arm achieved a partial respon e (29% vs 46%). 
Furtado et al20 compared a combination of bortezomib (an inhibitor of the 26S proteasome),  
cyclophosphamide, doxorubicin, vincristine and prednisolone (V-CHOP) for a maximum of 8 
cycles to CHOP in MCL patients who had been treated with at least 1 prior line of therapy. The 
phase II trial recruited 46 patients and was stopped early by the independent data monitoring 
committee due to significant differences in overall survival between the 2 cohorts. After a 
median follow up of 34 months, a non-significant improvement in PFS was observed with the  
V-CHOP combination when compared to CHOP alone (HR 0.60 [95% CI 0.31-1.15]; p=0.12).  
The median PFS observed with the V-CHOP combination was 16.5 months compared to 8.1 
months with CHOP, with a significant improvement in OS achieved with V-CHOP (HR 0.37 
[95% CI 0.16-0.83]; p=0.01). A median OS of 35.6 months with V-CHOP was substantially 
longer than that observed with CHOP, 11.8 months. Te addition of bortezomib to CHOP 
resulted in a superior ORR when compared to CHOP alone (82.6% vs 47.8%, p=0.01). A non-
significant improvement in complete response rates (34.8% vs 21.7%, p=0.33) and partial 
response rates (47.8% vs 26.1%, p=0.13) were also noted.  
Rummel et al22 compared bendamustine and rituximab (B-R) to fludarabine and rituximab (F-R) 
in a mixed cohort of patients who had received at le st 1 prior therapy. Fifty one percent of 
patients had FL, 21% had MCL, 11% had Waldenstrom’s macroglobulinaemia (WM), 8% had 
marginal zone lymphoma (MZL), 8% had lymphoplasmacytic l mphoma and an additional 1% 
had low grade unclassified. A maximum of 6 cycles of either chemotherapy combination was 
administered to 230 patients. The protocol was amended during the course of the trial to include 
rituximab maintenance therapy for patients who responded to B-R or F-R, as maintenance 
rituximab treatment had been approved for patients with FL. In patients with MCL, PFS was 
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statistically significantly improved in the B-R arm (HR 0.45 [95% CI 0.22-0.76]; p=0.01), with a 
median PFS of 17.6 months achieved for B-R compared with 4.7 months for F-R. An 
improvement in median OS was also observed (B-R group 35.3 months vs 20.9 months F-R, 
p=not reported). The impact of maintenance rituximab w s not reported for MCL patients. A 
superior ORR for MCL patients receiving B-R was achieved (70.8% vs 26.1%). Both the 
complete response rate (37.5% vs 13%) and the partial response rate (33.3% vs 13%) were 
substantially higher for MCL patients treated with B-R compared to patients treated with F-R.   
Trneny et al23 compared oral lenalidomide to investigator’s choice (IC) single agent 
chemotherapy in 254 MCL patients. They had to have been treated with at least 1 combination 
chemotherapy regimen comprising an alkylating agent and one or more of an anthracycline, 
cytarabine or fludarabine with or without rituximab. After a median follow up of 15.9 months, 
PFS was statistically significantly improved with lenalidomide (HR 0.61 [95% CI 0.44-0.84] 
p=0.004) when compared to IC  with a prolonged median PFS of 8.7 months compared to 5.2 
months in the IC arm. A significant improvement was demonstrated in favour of lenalidomide 
when compared to the majority of the individual IC therapies. A non-statistically significant 
difference in OS was reported for patients treated with lenalidomide compared with patients 
treated with IC (HR 0.89 [95% CI 0.62-1.28]; p=0.45). Median OS was 27.9 months with 
lenalidomide compared to 21.2 months with IC. The trial was not powered to demonstrate a 
survival difference between the 2 arms and was further compounded by patients’ crossing over to 
the lenalidomide arm on disease progression. A significa t improvement in ORR was observed 
for patients receiving lenalidomide treatment when compared to IC chemotherapy (40% vs 11%, 
p<0.001). The CR rate was 5% with lenalidomide vs 0%, (p=0.043). The PR rate was 35% vs 
11% IC). The duration of response was significantly prolonged with lenalidomide compared to 
IC (16.1 months vs 10.4 months, p=0.043).
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
Safety 
A summary of grade 3 or higher haematological toxicities observed in the trials is presented in 
figure 3.  Patients treated with ibrutinib had a longer duration of treatment exposure compared to 
the control arm in the trial led by Dreying et al17 (14.4 months vs 3 months) with a mean relative 
dose intensity of 99.9% for ibrutinib vs 81.8% for temsirolimus. Adverse events caused 
treatment discontinuation and dose reductions in 6% and 4% of patients in the ibrutinib arm 
compared with 26% and 43% respectively for the comparator group.  
The median duration of temsirolimus 175/75mg treatment was more than double that of IC (12 
weeks vs 5 weeks) in the trial led by Hess et al.21 Significantly higher rates of thrombocytopenia, 
and anaemia were observed with temsirolimus. In contrast, leucopenia was more frequent with 
IC chemotherapy than higher dose temsirolimus (all gr des 15% vs 40% IC), as was neutropenia 
(all grades 24% vs 40% IC). Twenty two percent of patients in the temsirolimus 175/75mg arm 
discontinued treatment due to an adverse event compared to 11% in the IC arm.  
The frequency of grade 3/4 haematological toxicities was comparable across both treatment 
groups in the trial by Forstpointner et al18 except for lymphocytopenia which was more common 
across grades 1-4 in the R-FCM arm when compared to the FCM arm The extended use of 
rituximab during the maintenance phase of the trial19 did not result in any significant differences 
of adverse events between the two arms.  
 
Furtado et al20 reported a similar rate of grade 3 or higher thromb cytopenia between the two 
arms, however a significant increase in the rate of >grade 3 neutropenia was observed in the 
experimental arm and translated to a higher rate of f brile neutropenia with the V-CHOP 
regimen. Non-neutropenic infection rates were also higher, however, these were primarily low 
grade.  
Both bendamustine-rituximab (B-R) and fludarabine-rituximab (F-R) combinations were well 
tolerated by patients in the trial by Rummel and colleagues.22 The dose intensity in the B-R 
group was 96.3% and was 99.5% in the F-R arm, indicating good tolerability for either regimen.
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Figure 3 – Grade 3 or Higher Haematological Toxicites 
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Dose reductions were more common in the lenalidomide group (41% vs 17%)23 but 
discontinuations were more common in the IC group (5% vs 16%). Rates of >grade 3 
neutropenia were higher in the lenalidomide arm, with febrile neutropenia reported in 6% of 
patients receiving lenalidomide compared to 2% of patients receiving IC. Rates of anaemia were 
comparable with thrombocytopenia being higher in the IC arm.  
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Unpublished and Ongoing Trials 
Four trials35,36,37,38 were presented at the 58th annual meeting of the American Society of 
Haematology (ASH) held in San Diego from 3-6 Decembr, 2016, all of which assessed 
combinations of treatments in relapsed/refractory MCL. All of these trials were single arm 
studies but give an indication of emerging potential future management approaches.  Jerkeman et 
al35 on behalf of the Nordic Lymphoma Group combined ibrutinib with lenalidomide and 
rituximab. The authors reported that out of the 50 patients enrolled to date, 29 were evaluable for 
response achieving an impressive ORR rate of 83% and CR of 41%, with median PFS not 
reached.  Morschhauser et al38 presented results on behalf of the LYSA group from their study 
combining lenalidomide with obinutuzumab, an anti-CD20 monoclonal antibody. Seven MCL 
patients completed the induction phase and achieved an ORR of 38.5% with CR in 23.1% as 
evaluated by revised IWG 2007 criteria.25 These improved ORR and CR rates would indicate a 
deeper response with the combination of therapies, which may in time translate to a longer PFS 
and overall survival for patients.  
As of December 2016, there were 85 ongoing trials (www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu) aiming to recruit more than 2300 patients with R/R MCL to 
evaluate monotherapies and combinations of agents. Of these 85 trials, 53 are phase I or phase 
I/II trials, 26 are in phase II, one trial is phase III and one trial is phase IV. The remaining four 
trials are either retrospective or stated as pilot studies with no further details. Only the phase III 
trial is a randomised controlled trial (appendix 4). Of the remaining 26 on-going phase II trials, 
13 are evaluating combinations of treatments and 13 are assessing monotherapies. Ibrutinib is 
included in five combination trials, lenalidomide is included in three combination studies, one of 
which is with bendamustine, and bortezomib is combined with additional treatments in two 
trials.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
Discussion 
There is no consensus about the standard of care for lapsed/refractory mantle cell lymphoma 
and current UK2, EU4 and US15 guidelines reflect this. As demonstrated by the search results 
there are many published studies assessing treatment regimens for this disease, but the vast 
majority are single arm, non-randomised trials thatrely on historical controls for comparison. 
Indeed, bortezomib, ibrutinib and lenalidomide all received marketing authorisations based on 
single arm phase II trials30,31,32 which may reflect the unmet medical need for this group of 
patients at the time. There is a noticeable lack of randomised controlled trials (RCT) evaluating 
treatments for relapsed/refractory mantle cell lymphoma, which limited the scope of this 
systematic review. Only seven RCTs17,18,19,20,21,22,23 were identified for this review, six of which 
were distinct trials and of these, only two met all the criteria set out in the Cochrane’s 
Collaboration tool for assessing risk of bias.  
Three of the trials had mixed populations. MCL is arare but aggressive B-cell malignancy which 
behaves quite differently to other sub-types of non-H dgkin lymphoma resulting in distinctive 
responses to treatments as demonstrated in the trial by Rummel et al.22 In this trial MCL patients’ 
receiving the combination of bendamustine and rituximab achieved a median PFS of 17.6 
months. In contrast, patients with follicular lymphoma achieved a median PFS of 54.5 months 
with the same regimen. These were exploratory sub-group analyses, nevertheless this highlights 
the need to evaluate treatments in a pure MCL population in order to draw clinically meaningful 
conclusions. It can be challenging to accrue sufficient number of patients to a trial when the 
disease is rare, and collaborative research groups have been established with this in mind. 
Forstpointner et al18 had only included 48 patients with MCL when furthe r cruitment was 
halted due to a significant advantage observed in the R-FCM arm, which had a mixed population 
of lymphoma sub-types. The trial by Furtado et al20 planned to recruit 90 patients, but as the trial 
was stopped early due to a significant difference i survival observed at the first predetermined 
evaluation point, only 46 patients were included. Neither trial was statistically designed for such 
small numbers, therefore the statistical significance of the results may be unreliable. Indeed the 
median PFS observed with V-CHOP treatment was double that of CHOP alone in the trial 
conducted by Furtado and colleagues20 and yet this did not achieve statistical significan e.  
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It is difficult to make meaningful comparisons of effectiveness across the included trials in this 
review as the inclusion/exclusion criteria differed between the trials. The trial by Dreyling et al17 
excluded patients with an ECOG PS above 1 whilst the remaining trials allowed patients with PS 
0-2.20,21,22,23 The majority of trials included patients who had received at least 1 line of prior 
therapy17,18,20,22,23 but these prior therapies differed between the trials and may have had some 
impact on the outcomes achieved. Prior rituximab therapy may have introduced outcome bias to 
those trials allowing prior exposure. Rule et al28 has demonstrated that the addition of rituximab 
to fludarabine-based chemotherapy in newly diagnosed MCL patients improved OS resulting in a 
reduction in the hazard of death by 31%.  In addition it has been suggested that prior bortezomib 
treatment sensitises MCL to subsequent therapies.29 Other baseline factors that may impact 
outcomes include time from initial diagnosis to randomisation - the longer time may suggest that 
these patients have more indolent disease as they can safely wait to start therapy. The proportion 
of patients that have the more difficult to treat bl stoid histology will impact on outcomes and 
the split between patients who have relapsed disease and refractory disease will influence, as  
refractory are generally a harder-to-treat sub-type. Additional factors that need to be considered 
when comparing trials are the differences in MIPI scores, the proportion of patients with high 
Ki67 scores indicating more aggressive disease and other biological factors such as TP53 
mutation or SOX11 status that will impact outcome.The ideal would be to have these balanced 
between the arms of each trial and stratification prior to randomisation may achieve this. That 
said, in a rare disease this can be difficult to achieve in practice. Blastoid histology represents a 
small proportion of the total MCL population but it is important that patients with this sub-type 
are included in trials in order to collect data on how they respond to various treatments. It would 
not be feasible to run a trial on this sub-type alone, therefore imbalances in baseline 
characteristics of this nature between treatment arms need to be tolerated whilst acknowledging 
that they may impact results.  
The response criteria by which outcomes were measurd differed between the studies. It is 
important that consistent definitions of endpoints are used allowing for comparisons among 
clinical trials.  International Working Group criteria, 199926 were revised in 200725 and 
eliminated the need for the response criterium, complete response unconfirmed (CRu) and 
incorporated the assessment of extranodal disease. In a trial recently presented at the 58th Annual 
Meeting of the American Society of Haematology (ASH), 201635 two analyses were conducted 
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within the same trial,  one using the 1999 IWG criteria26 demonstrating an ORR of 46.2% and a 
CR/CRu of 15.4%.  The other used the revised IWG criteria 200725 and reported an ORR of 
38.5% and CR of 23.2%, thus demonstrating some diffrences in response rates depending on 
the criteria used. Four of the trials17,20,21,23 in this review used the revised 2007 IWG criteria25 
whereas both trials by Forstpointner et al18,19 used IWG 1999 criteria.26 The revised criteria25 
also provide clear definitions of time to event outcomes, for example, PFS and OS are measured 
from the time of randomisation to the date of disease progression or death from any cause.  
Definitions of progression free survival (PFS) were inconsistent between the trials. Three 
trials17,21,23 used the IWG definition. Two trials18,22 however, used the definition: “Progression 
free survival is the interval between the start of treatment/first treatment and documentation of 
progressive disease or death from any cause”. One trial20 did not give a definition of PFS. The 
authors stated that one of the secondary outcomes was “median time to progression of disease”, 
however, reported PFS in the results. 
The trial by Hess et al21 evaluated two different dosing regimens of temsirolimus (175/75mg and 
175/25mg) to a control arm of IC chemotherapy, and the results led to the regulatory approval of 
the 175/75mg dose in the EU. Dreyling et al17 compared ibrutinib to temsirolimus 175/75mg. 
There are some similarities when comparing baseline characteristics between the two trials, thus 
it would be feasible to make comparisons between th outcomes of these two trials. What is 
striking is that across all outcome measures in the Dreyling et al17 study, temsirolimus 
outperformed those achieved in the temsirolimus 175/75mg arm of the trial by Hess et al,21 
although the duration of response reported was similar between the two trials. Patients in the 
Hess trial21 had received two to seven prior therapies (48% had received 4-7 prior treatments) 
compared to at least one in Dreyling’s study17 (68% had received a median of 1-2) which might 
account for the poorer performance of temsirolimus, s ggesting that earlier treatment is more 
effective. Indeed, the abstract presented by Rule et al33 at the 21st congress of the European 
Haematology Association (EHA), 2016, supports this. The authors here reported survival 
outcomes for ibrutinib by number of lines of prior therapy, indicating that earlier treatment is 
more effective. That said, ibrutinib was significantly better than temsirolimus across all outcome 
measures in the trial by Dreyling et al.17 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
The addition of rituximab to chemotherapy regimens for the treatment of MCL patients has been 
established in a number of trials. Included in thisreview are the trials by Forstpointner et al18,19 
which demonstrated that the addition of rituximab to the combination of fludarabine, 
cyclophosphamide and mitoxantrone followed by rituximab maintenance for patients in 
remission improved response rates and overall survival. Maintenance rituximab resulted in a 
higher proportion of patients experiencing ongoing remissions beyond 2 years. The impact of 
rituximab on the outcome for MCL patients, influencd the decision to halt the trial by Furtado et 
al20 early. The authors had not incorporated rituximab into the design of their study, but during 
the recruitment period it had become part of standard c re in the UK. Rummel et al22 began 
accrual for their trial in October 2003, however the authors amended their protocol to allow 
patients who responded to either B-R or F-R chemotherapy regimens to receive maintenance 
rituximab following the publication of Forstpointner t al’s trial.19 They conducted a sub-group 
analysis on the total population, comparing those patients who received maintenance and those 
who did not. The results confirmed the impact that m intenance rituximab had on PFS and OS in 
the R/R setting following remission with induction chemotherapy. Maintenance rituximab 
reduced the risk of death or disease progression by 48% (PFS p=0.01, OS p=0.03). The group of 
MCL patients who received maintenance rituximab wastoo small to conduct this analysis upon. 
However, the trial reported by Rummel et al34 t the annual meeting of the American Society of 
Clinical Oncology (ASCO), 2016 conducted in the first line setting, may give some indication of 
what might be expected in MCL patients. No statistically significant difference in PFS was 
observed between patients receiving maintenance rituximab following B-R chemotherapy 
compared with patients not receiving maintenance rituximab (HR 0.64, 95% CI 0.36–1.14, 
p=0.130). This trial recruited 120 patients with newly diagnosed MCL and the authors concluded 
that after a median observation time of 4.5 years they were not able to demonstrate statistical 
evidence supporting the benefit of rituximab maintenance after B-R. 
Only one treatment, temsirolimus, appeared in more than one trial, which meant that the results 
from each trial could not be quantitatively pooled by meta-analysis. Whilst a limited network 
meta-analysis could theoretically have been done between Dreyling et al17 and Hess et al21 as 
they both had a temsirolimus arm, the fact that Hess et al21 had as a comparator IC meant that it 
was impossible to evaluate the effectiveness of temsirolimus against particular drugs, making the 
comparisons meaningless.   
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As the majority of patients with MCL are elderly, tolerability of treatment is an important factor 
when comparing different therapies, and should be evaluated on the per protocol population to 
accurately reflect adverse events in patients actually receiving drug. Grade 3 or higher 
haematological adverse event rates varied considerably between the included trials.  The rates of 
>grade 3 haematological toxicities were low with eith r the combination of bendamustine and 
rituximab or fludarabine and rituximab in Rummel et al’s trial22 with high dose intensities 
achieved in both arms of the trial. Ibrutinib was al o well tolerated with low rates of 
myelosuppression despite treatment exposure being 3 times as long with ibrutinib compared to 
temsirolimus 175/75mg.17 Dose reductions were uncommon with ibrutinib whilst 43% of 
patients receiving temsirolimus 175/75mg required a dose reduction due to adverse events. 
Nearly a quarter of patients being treated with temsirolimus 175/75mg in the trial conducted by 
Hess et al21 discontinued treatment due to an adverse event. Both of these trials suggest that 
temsirolimus at the approved dose of 175/75mg is poorly tolerated. In Forstpointner and 
colleagues trial19, it was encouraging to note that rituximab maintenance did not result in 
substantial additional treatment-associated haematological toxicities with >grade 3 adverse event 
rates very similar between the maintenance and no maintenance arms.  
Some of the novel agents identified in this review are now being evaluated in the front-line 
setting which will impact on the choice of agent for when these patients subsequently relapse. A 
UK study39 evaluating ibrutinib and rituximab against a rituxmab and chemotherapy 
combination in newly diagnosed patients with MCL who are not eligible for intensive treatment 
is ongoing. Results are expected in 2022. In addition, the SHINE trial is assessing the 
combination of ibrutinib with B-R in newly diagnosed patients40. A similar trial evaluating the 
combination of the second generation BTK inhibitor, acalabrutinib with B-R41 is ongoing, with 
results due in February 2021. If these prove to be successful the paradigm for relapsed or 
refractory disease will shift and subsequent trials for R/R MCL will need to include patients who 
have received prior ibrutinib or acalabrutinib treament. A Spanish trial42 is evaluating the 
combination of ibrutinib and rituximab in newly diagnosed patients with the indolent form of 
MCL. This trial is expected to report results in Jau ry 2023. Several trials43,44,45 are evaluating 
the role of lenalidomide in the first line setting, either in combination with chemotherapy or as 
maintenance following chemotherapy induction. The E1411 trial46 is evaluating the combination 
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of bortezomib with B-R as induction followed by rituximab+/- lenalidomide as maintenance. 
Results are expected in March 2019.  
There are a number of new agents being assessed for R/R MCL, either as monotherapy or in 
combination with established treatments: venetoclax (BCL-2 inhibitor), idelalisib and buparlisib  
(PI3Kδ inhibitors), the second generation proteasome inihibitor carfilzomib, daratumumab (an 
anti-CD38 mononclonal antibody) and genetically engineered chimeric antigen receptor T-cells 
(CAR T-cells). All are currently in single arm trials.  
As the landscape of treatment options for the management of R/R MCL becomes more 
complicated, comparative studies will be required to evaluate the relative advantages of one 
treatment over another in order to ensure the optimal use of the available therapies. The protocol 
only permitted the inclusion of randomised controlled trials as this study design provides the best 
evidence for effectiveness of treatments. Single arm trials may provide additional information to 
clinicians about efficacy of treatment options for this rare disease but these are biased by nature 
of their design. It is concerning that only one of the on-going studies is an RCT. Careful 
consideration should be given to future trial design to ensure that meaningful evaluation of 
effectiveness of treatments can be undertaken. 
The challenging factor is that MCL remains a rare malignancy with a small pool of patients from 
which to recruit to trials. Collaboration between rsearch groups and agreement of standards for 
clinical trials is essential. In addition to this, utilising adaptive trial designs for assessing the 
relative merits of treatments may help in addressing this challenge. Multi arm multi stage 
(MAMS) trials have been adopted in some therapeutic areas in order that a number of novel 
treatments can be compared simultaneously to a shared control group47. This can result in 
answers to research questions being provided more quickly and cost effectively with a smaller 
number of patients, and may be a suitable approach to adopt for evaluating future treatments or 
combinations of treatments for MCL patients.  
The scarcity of high-quality RCTs in MCL highlights the difficulty in evaluating comparative 
efficacy and safety of new therapies. Historical studies lack common comparators, exhibit 
differences in inclusion criteria and have small sample sizes. Although prognostic indicators 
such as the sMIPI score or blastoid variant were report d in some of the studies, none of the 
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trials reported outcomes according to these important factors, due to the small numbers of 
patients in these groups. The original protocol intended to undertake a sub-group analysis for 
these prognostic indicators but due to the lack of data this analysis was not possible. 
Nevertheless, this review should help to guide treatm nt selection for elderly patients with R/R 
MCL who are unsuitable for intensive chemotherapy or transplant.
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Appendices   
1. Medline (Ovid) Search Strategy 
1. Lymphoma, Mantle-cell.mp. or *mantle cell lymphoma/ 
2. Lymphoma, Non-Hodgkin.mp. or *nonhodgkin lymphoma/  
3. B-cell.mp. or *B lymphocyte/  
4. 1 or 2 or 3  
5. Drug therapy.mp. or drug therapy/  
6. immunotherapy.mp. or immunotherapy/  
7. molecular targeted therapy.mp. or molecularly targeted therapy/  
8. biological therapy.mp. or biological therapy/  
9. combined modality therapy.mp. or multimodality can er therapy/  
10. antineoplastic agents.mp. or antineoplastic agent/  
11. lenalidomide.mp. or lenalidomide/  
12. ibrutinib.mp. or ibrutinib/  
13. thalidomide.mp. or thalidomide/  
14. bortezomib.mp. or bortezomib/  
15. temsirolimus.mp. or temsirolimus/  
16. everolimus/ or everolimus.mp.  
17. BTK inhibitor.mp. or Bruton tyrosine kinase inhbitor/  
18. proteasome inhibitor.mp. or proteasome inhibitor/ or ixazomib/  
19. immunomodulating agent/ or imid.mp.  
20. combination chemotherapy/ or chemotherapy/ or multi odal chemotherapy/ or cancer 
combination chemotherapy/ or chemotherapy.mp.  
21. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20  
22. 4 and 21  
23. limit 22 to (randomized controlled trial and yr="1994 -Current") 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
2. Embase (Ovid) Search Strategy 
1. Lymphoma, Mantle-cell.mp. or *mantle cell lymphoma/  
2. Lymphoma, Non-Hodgkin.mp. or *nonhodgkin lymphoma/  
3. B-cell.mp. or *B lymphocyte/  
4. 1 or 2 or 3  
5. Drug therapy.mp. or drug therapy/  
6. immunotherapy.mp. or immunotherapy/  
7. molecular targeted therapy.mp. or molecularly targeted therapy/  
8. biological therapy.mp. or biological therapy/  
9. combined modality therapy.mp. or multimodality can er therapy/  
10. antineoplastic agents.mp. or antineoplastic agent/  
11. lenalidomide.mp. or lenalidomide/  
12. ibrutinib.mp. or ibrutinib/  
13. thalidomide.mp. or thalidomide/  
14. bortezomib.mp. or bortezomib/  
15. temsirolimus.mp. or temsirolimus/  
16. everolimus/ or everolimus.mp.  
17. BTK inhibitor.mp. or Bruton tyrosine kinase inhbitor/  
18. proteasome inhibitor.mp. or proteasome inhibitor/ or ixazomib/  
19. immunomodulating agent/ or imid.mp.  
20. combination chemotherapy/ or chemotherapy/ or multi odal chemotherapy/ or cancer 
combination chemotherapy/ or chemotherapy.mp.  
21. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20  
22. 4 and 21  
23. limit 22 to (randomized controlled trial and yr="1994 -Current
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3. Quality Assessment of Included Trials in MCL 
 
Reference Criteria from Cochrane 
Collaboration’s Tool 
Assessment Notes 
Dreying et al, 201617 Was the allocation sequence adequately 
generated? 
Yes Central randomisation was used….based on a 
computer-generated randomisation schedule. 
Randomisation was balanced by using 
randomly permuted blocks. 
 Was allocation adequately concealed? Yes Randomisation scheme was implemented 
within the interactive web response system 
 Was participant and personnel 
knowledge of the allocated intervention 
prevented during the study?  
Unclear Open label. Patients and investigators were 
unmasked to treatment assignment 
 Was knowledge of the outcome 
assessment adequately prevented during 
the study? 
Yes Outcome assessments were conducted by an 
independent review committee using validated 
IWG criteria 
 Were incomplete outcome data 
adequately addressed? 
Yes All data was accounted for. Analysis 
conducted on ITT basis.  
 Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Yes All pre-specified outcomes reported 
 Was the study apparently free of other 
problems that could put it at a high risk 
of bias? 
Yes Although protocol was amended to allow cross 
over to investigational arm on progression this 
would have introduced bias against the 
investigational drug 
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Forstpointner et al, 
200418 
Was the allocation sequence adequately 
generated? 
Yes Central randomisation procedure done by 
computer programme using random 
permutated blocks 
 Was allocation adequately concealed? Yes  Central allocation was done by telephone 
 
 Was participant and personnel 
knowledge of the allocated intervention 
prevented during the study?  
Unclear Open label. Patients and investigators were 
unmasked to treatment assignment 
 Was knowledge of the outcome 
assessment adequately prevented during 
the study? 
Unclear An open-label study. Responses were 
evaluated using validated IWG criteria, 
although it wasn’t stated whether this was 
centrally or locally reviewed  
 Were incomplete outcome data 
adequately addressed? 
Yes Out of 147 randomised to the trial, 128 
patients were evaluable; authors accounted for 
the remaining 19 patients 
 Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Yes All pre-specified outcomes were reported 
 Was the study apparently free of other 
problems that could put it at a high risk 
of bias? 
Yes Although the trial was stopped early, this was 
pre-specified and allowed stopping when a 
level of significance was reached. The arms 
and baseline characteristics were well balanced 
    
Forstpointner et al, 
200619 
Was the allocation sequence adequately 
generated? 
Yes Central randomisation procedure done by 
computer programme using random 
permutated blocks 
 Was allocation adequately concealed? Yes  Central allocation was done by telephone 
 
 Was participant and personnel 
knowledge of the allocated intervention 
prevented during the study?  
Unclear Open label. Patients and investigators were 
unmasked to treatment assignment 
 Was knowledge of the outcome 
assessment adequately prevented during 
Unclear Responses were evaluated using validated 
IWG criteria, although it wasn’t stated whether 
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the trial? this was centrally or locally reviewed  
 Were incomplete outcome data 
adequately addressed? 
Yes Authors accounted for all patients and gave 
reasons for those not included in the analysis 
 Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Yes All pre-specified outcomes were reported 
 Was the study apparently free of other 
problems that could put it at a high risk 
of bias? 
Yes Analysis included 38 patients who received 
FCM as induction instead of R-FCM. If any 
bias introduced it would be against 
investigational arm 
    
Furtado et al, 201420 Was the allocation sequence adequately 
generated? 
Unclear Method of sequence generation was not 
described. Insufficient information to allow 
judgement 
 Was allocation adequately concealed? Unclear Method of concealment was not described. 
Insufficient information to allow judgement 
 Was participant and personnel 
knowledge of the allocated intervention 
prevented during the study?  
Unclear Open label. Patients and investigators were 
unmasked to treatment assignment 
 Was knowledge of the outcome 
assessment adequately prevented during 
the trial? 
Unclear Responses were evaluated using validated 
IWG criteria, although it wasn’t stated whether 
this was centrally or locally reviewed 
 Were incomplete outcome data 
adequately addressed? 
Yes Out of 46 patients included in the trial, 41 
were assessable. The authors accounted for the 
5 non-assessable patients and included them in 
the analysis as non-responders. 
 Are reports of the study free of 
suggestion of selective outcome 
reporting? 
No The protocol pre-specified time to progression 
and quality of life as secondary endpoints.  
These were not reported. 
 Was the study apparently free of other 
problems that could put it at a high risk 
of bias? 
No There were imbalances in the baselines 
characteristics: there were more men in the 
CHOP arm (91% vs 65%) time since diagnosis 
was shorter in the CHOP arm (19.7 vs 24.7 
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months) and less patients had received prior 
rituximab in the CHOP arm (17% vs 43%). 
    
Hess et al, 200921 Was the allocation sequence adequately 
generated? 
Unclear Method of sequence generation was not 
described. Insufficient information to allow 
judgement 
 Was allocation adequately concealed? Unclear Method of concealment was not described. 
Insufficient information to allow judgement 
 Was participant and personnel 
knowledge of the allocated intervention 
prevented during the study?  
Unclear Open label. Patients and investigators were 
unmasked to treatment assignment 
 Was knowledge of the outcome 
assessment adequately prevented during 
the trial? 
Yes Outcome assessments were conducted by an 
independent review committee using validated 
IWG criteria on an ITT basis 
 Were incomplete outcome data 
adequately addressed? 
Yes There were no missing outcome data. 
 Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Yes All pre-specified outcomes were reported 
 Was the study apparently free of other 
problems that could put it at a high risk 
of bias? 
Yes Baseline characteristics were generally well 
balanced. Where imbalances occurred these 
were these were in favour of IC: fewer patients 
with bone marrow involvement (39% vs 
54%),fewer patients with blastoid variant (7% 
vs 17%) and more patients with prior 
bortezomib therapy (31% vs 19%). 
    
Rummel et al, 201622 Was the allocation sequence adequately 
generated? 
Yes Randomisation was conducted centrally 
according to pre-specified randomisation lists 
with permuted blocks of randomly variable 
block size 
 Was allocation adequately concealed? Yes Patients were randomised centrally under 
concealment 
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 Was participant and personnel 
knowledge of the allocated intervention 
prevented during the study?  
Unclear Open label. Patients and investigators were 
unmasked to treatment assignment 
 Was knowledge of the outcome 
assessment adequately prevented during 
the trial? 
No Patients were assessed locally and not by an 
independent review committee. Response 
criteria was not referenced in the study. 
 Were incomplete outcome data 
adequately addressed? 
Yes Analysis was conducted on a per protocol 
basis. Authors accounted for all patients and 
gave reasons for those not included in the 
analysis 
 Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Yes All pre-specified outcomes were reported 
 Was the study apparently free of other 
problems that could put it at a high risk 
of bias? 
Yes Baseline characteristics were similar between 
the 2 groups 
    
Trneny et al, 201623 Was the allocation sequence adequately 
generated? 
Yes Permuted-block randomisation with a block 
size of 6 resulting in 50 blocks in each stratum 
was used 
 Was allocation adequately concealed? Yes  A centralized interactive voice-response 
system was used to allocate patients 
 Was participant and personnel 
knowledge of the allocated intervention 
prevented during the study?  
Unclear Open label. Patients and investigators were 
unmasked to treatment assignment 
 Was knowledge of the outcome 
assessment adequately prevented during 
the trial? 
Yes Outcome assessments were conducted by an 
independent review committee using validated 
IWG criteria 
 Were incomplete outcome data 
adequately addressed? 
Yes All data was accounted for. Analysis 
conducted on ITT basis.  
 Are reports of the study free of 
suggestion of selective outcome 
reporting? 
Yes All pre-specified outcomes reported 
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 Was the study apparently free of other 
problems that could put it at a high risk 
of bias? 
Yes Although protocol allowed cross over to 
investigational arm on progression this would 
have introduced bias against the 
investigational drug 
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4. On-Going Trials in Relapsed/Refractory MCL  
NCT Identifier Study Design Line of Treatment 
Target 
Patient 
Numbers 
Primary Outcome Completes 
COMBINATION TRIALS       
NCT02460276 
A Phase II Trial of Ibrutinib, Lenalidomide 
and Rituximab for Patients 
With Relapsed/Refractory Mantle Cell 
Lymphoma 
At least 1 
rituximab-
containing prior Rx  
50 
ORR based on PET and 
CT 
Mar 2017 
NCT01880567 
A Phase II Study of Ibrutinib Plus Rituximab 
in Patients With Relapsed/Refractory Mantle 
Cell Lymphoma or Elderly Patients With 
Newly Diagnosed Mantle Cell 
Lymphoma (MCL) 
At least 1 prior 
treatment 
100 ORR Dec 2019 
NCT01737177 
Bendamustine, Lenalidomide and Rituximab 
(R2-B) Combination as a Second-Line 
Therapy for First Relapsed-Refractory 
Mantle Cell Lymphomas: A Phase II Study 
At least 1 prior 
treatment 
42 
CR based on IWG 2007 
and maintenance PFS 
Jan 2017 
NCT01996865 
A Phase 3B Randomized Study of 
Lenalidomide (CC-5013) Plus Rituximab 
Maintenance Therapy Followed by 
Lenalidomide Single-Agent Maintenance 
Versus Rituximab in Subjects 
With Relapsed/Refractory Follicular, 
Marginal Zone, or Mantle Cell Lymphoma 
At least 1 prior 
treatment 
500 PFS based on IWG 1999 Mar 2023 
NCT00980395 
A Phase II, Open-Label Study of Bortezomib 
(Velcade), Cladribine and Rituximab (VCR) 
in Advanced, Newly Diagnosed 
and Relapsed/Refractory Mantle Cell and 
Indolent Lymphomas 
Not stated 39 PFS at 2 years Dec 2021 
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NCT02840539 
A Phase 2 Trial to Evaluate the Efficacy of 
Bortezomib, Cytarabine, and Dexamethasone 
in Patients With Relapsed or Refractory 
Mantle Cell Lymphoma 
1-3 prior lines of 
treatment 
32 ORR Feb 2020 
NCT02736617 
A Phase II Study of Obinutuzumab (GA-
101) in Combination With Ibrutinib (I) for 
the Treatment of Relapsed Mantle Cell 
Lymphoma 
At least 1 prior 
treatment 
20 Best ORR of CR/PR July 2021 
NCT02471391 
A Phase 2 Study of ABT-199 in 
Combination With Ibrutinib in the Treatment 
of Patients With Relapsed or Refractory 
Mantle Cell Lymphoma (AIM Study) 
At least 1 prior 
treatment 
24 
CR at 16 weeks based on 
IWG 2007 
June 2018 
NCT01796470 
A Phase 2, Open-Label Study Evaluating the 
Efficacy, Safety, Tolerability, and 
Pharmacodynamics of GS-9973 
(entospletinib)in Combination With 
Idelalisib in Subjects 
With Relapsed or Refractory Hematologic 
Malignancies 
Not stated 66 ORR June 2017 
NCT00764517 
Phase II Study of Vorinostat (SAHA), 
Cladribine, and Rituximab (SCR) in Mantle 
Cell Lymphoma, Chronic Lymphocytic 
Leukemia, and Relapsed B Cell Non-
Hodgkin Lymphoma 
Not stated 66 ORR based on IWG 2007 Dec 2016 
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NCT01562977 
Prospective, Open-label, Multicentric, ph. II 
Study of R-GemOx and Dexametasone in 
Patients With 
Agressive Lymphomas Refractory or Relaps
ed to Previous Treatment and Non Eligible 
for High-dose Chemotherapy Followed by 
Autologous Stem Cell Transplanted 
Not stated 129 ORR based on IWG April 2017 
NCT01812005 
A Phase II Study of MLN8237 
(alisertib)Alone and in Combination With 
Rituximab in Patients 
With Relapsed or Refractory B-Cell Non-
Hodgkin Lymphomas 
At least 1 prior 
treatment 
50 ORR to alisertib alone Dec 2016 
EudraCT:   
2015-004061-87 
 
A Phase 2 Study to Evaluate the Efficacy and 
Tolerability of IMGN529 in Combination 
with Rituximab in Patients with Relapsed 
and/or Refractory Diffuse Large B-Cell 
Lymphoma and Other Forms of Non-
Hodgkin Lymphoma 
 
At least 1 prior 
treatment 
75 Safety and ORR Not stated 
MONOTHERAPY TRIALS       
NCT02601313 
A Phase 2 Multicenter Study Evaluating the 
Efficacy of KTE-C19 in Subjects 
With Relapsed/Refractory Mantle Cell 
Lymphoma (r/r MCL) (ZUMA-2) 
Up to 5 prior 
treatments. Must 
have included 
anthracycline,or 
bendamustine-
containing regimen, 
anti-CD20 mAb 
and ibrutinib  
70 ORR based on IWG Sep-17 
NCT02042950 
A Phase II Study of Carfilzomib in the 
Treatment of Relapsed/Refractory Mantle 
Cell Lymphoma 
Not stated 60 ORR based on IWG 2007 Jul-21 
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NCT02413489 
An Open Label, Phase 2 Study to Evaluate 
Efficacy and Safety of Daratumumab 
in Relapsed or Refractory Mantle Cell 
Lymphoma, Diffuse Large B-Cell 
Lymphoma, and Follicular Lymphoma 
At least 2 prior 
lines of treatment 
210 ORR Jan-19 
NCT02488512 
Peptide Receptor Radionuclide Therapy With 
90Y-Dotatoc in Relapsed/Refractory Diffuse 
Large B Cell (DLBCL) and Mantle Cell 
Lymphomas (MCL) 
Not stated 35 ORR based on IWG Feb-18 
NCT02169180 
A Phase 2 Study of the Bruton's Tyrosine 
Kinase (BTK) Inhibitor Ibrutinib in Subjects 
With Relapsed or Refractory Mantle Cell 
Lymphoma (MCL) in Japan 
At least 1 prior 
treatment 
16 ORR based on IWG 2007 Jun-17 
NCT02267915 
An Open Multicenter Phase II Study of 
Efficacy and Toxicity of Maintenance 
Subcut. Rituximab After Induction With 
Rituximab in Patients 
With Relapsed or Refractory Mantle-cell 
Lymphoma Non-eligible for HSCT 
1-2 prior lines of 
treatment 
36 TTP 
2019 
November 
NCT01678417 
A Phase II Study of 131I-rituximab for 
Patients 
With Relapsed or Refractory Follicular 
or Mantle Cell Lymphoma 
Not stated 29 ORR Jun-17 
NCT01693614 
An Open-label Phase II Study of BKM120 in 
Patients 
With Relapsed and Refractory Diffuse Large 
B-cell Lymphoma, Mantle Cell Lymphoma 
and Follicular Lymphoma 
At least 1 prior 
treatment 
72 ORR Dec-16 
NCT02213926 
 
An Open-label, Phase 2 Study of ACP-196 in 
Subjects With Mantle Cell Lymphoma 
 
Not stated 124 ORR Jan-18 
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NCT02572453 
Phase 2 Study of AT13387 (Onalespib) in 
ALK+ ALCL, MCL, and BCL-6+ DLBCL 
Prior multi-agent 
chemo and 
ibrutinib or other 
BTK inhibitor 
50 
ORR, change in protein 
levels of ALK, BCL6 and 
cyclin D1 
Dec-16 
NCT01799889 
A Phase 2, Open-Label Study Evaluating the 
Efficacy, Safety, Tolerability, and 
Pharmacodynamics of GS-9973 
(entospletinib) in Subjects 
With Relapsed or Refractory Hematologic 
Malignancies 
Not stated 385 PFS May-19 
NCT02952508 
An Open-Label, Multicenter, Phase 2 Study 
of CLR 131 in Patients 
With Relapsed or Refractory (R/R) Select B-
Cell Malignancies 
1-2 prior treatments 80 ORR Mar-18 
NCT01261247 
A Phase II Study of the Histone Deacetylase 
(HDAC) Inhibitor LBH589 (Panobinostat) in 
Patients With Relapsed or Refractory Non-
Hodgkin Lymphoma 
At least 1 prior 
treatment 
41 ORR Nov-16 
 
